This article is intended for primary care clinicians, obstetricians, and other specialists who care for pregnant women.
The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.
Upon completion of this activity, participants will be able to:
As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 0.25
AMA PRA Category 1 Credit(s)™
. Physicians should only claim credit commensurate with the extent of their participation in the activity. Medscape Medical News has been reviewed and is acceptable for up to 300 Prescribed credits by the American Academy of Family Physicians. AAFP accreditation begins 09/01/07. Term of approval is for 1 year from this date. This activity is approved for 0.25 Prescribed credits. Credit may be claimed for 1 year from the date of this activity. AAFP credit is subject to change based on topic selection throughout the accreditation year.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page.
Follow these steps to earn CME/CE credit*:
CME Released: 7/14/2008
Valid for credit through: 7/14/2009, 11:59 PM EST
processing....
July 14, 2008 — Intake of n-3 polyunsaturated fatty acids (n-3 PUFAs) in late pregnancy may have prophylactic effects against asthma in children, according to the results of a randomized, prospective study reported in the July issue of the American Journal of Clinical Nutrition.
"Evidence suggests that asthma is rooted in the intrauterine environment and that intake of marine ...n-3 PUFAs in pregnancy may have immunomodulatory effects on the child," write Sjurdur F. Olsen, from Statens Serum Institut in Copenhagen, Denmark, and colleagues. "Our aim was to examine whether increasing maternal intake of n-3 PUFAs in pregnancy may affect offspring risk of asthma."
The study cohort was a population-based sample of 533 women with normal pregnancies in 1990 who were recruited and randomized at approximately gestational week 30 and who were asked to take study capsules until delivery. Participants were randomized 2:1:1 to receive four 1-g gelatin capsules per day containing fish oil providing 2.7 g n-3 PUFAs (n = 266); four 1-g, similar-appearing capsules per day containing olive oil (n = 136); or no oil capsules (n = 131).
Of 531 liveborn children, 528 were identified in registries, and 523 were still alive by August 2006. Using a mandatory registry that recorded diagnoses reported from hospital contacts, the investigators extracted diagnoses from the International Classification of Diseases, 10th Revision.
During a 16-year follow-up, an asthma-related diagnosis was reported in 19 children from the fish oil and olive oil groups, including 10 diagnosed with allergic asthma. For the fish oil vs the olive oil group, the hazard rate of asthma was reduced by 63% (95% confidence interval [CI], 8% - 85%; P = .03), and the hazard rate of allergic asthma was reduced by 87% (95% CI, 40% - 97%; P = .01).
"Under the assumption that intake of olive oil in the dose provided here was inert, our results support that increasing n-3 PUFAs in late pregnancy may carry an important prophylactic potential in relation to offspring asthma," the study authors write.
Limitations of this study include few data to evaluate the dose-response relationship between maternal intake of n-3 PUFAs and offspring asthma.
"Clearly, there is a need for both large RCTs [randomized clinical trials] with long follow-ups as well as mechanistic studies," the study authors conclude. "Trials should also be undertaken that test the potential immunomodulatory effects on the offspring of various doses of n-3 PUFAs supplemented during various time windows during gestation."
The European Union FP6 consortium, Early Nutrition Programming Project, The Danish Obesity Research Centre from the Danish Strategic Research Council, The Lundbeck Foundation, and The Danish Medical Research Council supported this study. The study authors have disclosed no relevant financial relationships.
Am J Clin Nutr. 2008;88:167-175.
The cause of asthma remains enigmatic. Maternal factors such as smoking, infections, and antibiotic use during pregnancy have been implicated in the occurrence of asthma and atopic disorders in the offspring as well as dietary intake of antioxidants, vitamins A and D, folate, and pollutants. These factors suggest that maternal intake of marine n-3 PUFAs, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) may affect immune function and the risk for asthma in the offspring.
This is a follow-up study of children of mothers who were in a randomized clinical trial during pregnancy who were assigned to either n-3 PUFA supplementation, olive oil placebo, or no supplementation, to examine their incidence of asthma.